Concurrent occurrence of adenocarcinoma and urothelial carcinoma of the prostate gland: A case report

doi:10.12998/wjcc.v12.i26.5952

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (39)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series.

Item

Count

PDF

HTML

Figures (1-6)

Sum=37

Sep 16, 2024 (publication date) through Jul 20, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Sep 16, 2024; 12(26): 5952-5959
Published online Sep 16, 2024. doi: 10.12998/wjcc.v12.i26.5952

Concurrent occurrence of adenocarcinoma and urothelial carcinoma of the prostate gland: A case report

Jhe Yuan Hsu, Yi Sheng Lin, Li Hua Huang, Tang Yi Tsao, Chao Yu Hsu, Yen Chuan Ou, Min Che Tung

Jhe Yuan Hsu, Yi Sheng Lin, Li Hua Huang, Chao Yu Hsu, Yen Chuan Ou, Min Che Tung, Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, Taichung 435403, Taiwan

Tang Yi Tsao, Department of Pathology, Tungs' Taichung MetroHarbor Hospital, Taichung 435403, Taiwan

Author contributions: Hsu JY, Lin YS, Huang LH, and Tsao TY contributed to patient care, data collection, and manuscript writing and editing; Hsu CY, Ou YC, and Tung MC contributed to conceptualization and supervision; All authors have read and approved the final manuscript.

Informed consent statement: Written informed consent was obtained from the patient for the publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Yi Sheng Lin, MD, Chief Doctor, Division of Urology, Department of Surgery, Tungs' Taichung MetroHarbor Hospital, No. 699 Section 8, Taiwan Boulevard, Wuqi District, Taichung 435403, Taiwan. tung12197@gmail.com

Received: February 25, 2024
Revised: June 15, 2024
Accepted: July 15, 2024
Published online: September 16, 2024
Processing time: 146 Days and 5 Hours

Core Tip

Core Tip: This report of synchronous adenocarcinoma and urothelial carcinoma (UC) of the prostate gland describes the unique prostate cancer manifestations in a male patient as well as the clinical journey from his initial symptoms of urinary retention and gross hematuria to the final treatment comprising robotic-assisted radical prostatectomy and bilateral pelvic lymph nodes dissection. This rare co-occurrence of two distinct cancer subtypes of the prostate gland without a history of UC of the urinary bladder and evident recurrence after treatment emphasizes the need for heightened diagnostic awareness and suggests novel oncogenic pathways and genetic predispositions.